Background {#Sec1}
==========

Globally, tuberculosis (TB) is the commonest opportunistic infection in HIV-infected patients, especially in resource-constrained settings \[[@CR1]\]. Mortality in co-infected patients varies across regions as reported previously \[[@CR2], [@CR3]\], however, in most regions TB is the most common cause of death among the HIV-infected adult population \[[@CR4]--[@CR6]\]. Prospective cohort studies demonstrated that HIV patients co-infected with TB have an increased risk of death \[[@CR5]\], and reduced mortality with appropriate TB treatment and initiation of antiretroviral therapy (ART) \[[@CR7], [@CR8]\]. Additionally, in patients with TB who present with advanced immunodeficiency (CD4 count \< 200 cells/mm^3^), early initiation of ART (\< 8 weeks after TB treatment initiation) increases survival, as demonstrated in several large clinical trials \[[@CR9]--[@CR12]\]. Efavirenz-based regimens were used in all of these studies \[[@CR9]--[@CR12]\]. The efficacy of other ART regimens in TB/HIV co-infected patients, and the relative efficacy of rifampicin- or rifabutin-containing regimens in patients receiving ART remains poorly studied \[[@CR13]--[@CR15]\]. Hence, National and regional guidelines provide minimal guidance on such ART regimens used concomitantly with tuberculosis treatment \[[@CR1], [@CR16]--[@CR22]\].

On the other hand, late presentation of HIV-positive adult patients into care is common in both resource-constrained and high-income settings \[[@CR23]--[@CR25]\] and episodes of opportunistic infection including TB, may occur within the first few months after initiation of ART \[[@CR8]\]. In most parts of the world with limited resources and a high burden of TB, efavirenz remains the preferred agent as the third component of ART regimens, as it has no clinically-significant interaction with rifampicin \[[@CR1], [@CR26]\]. However, tolerability and non-nucleoside reverse transcriptase inhibitor resistance may preclude use of efavirenz. In 2007, the WHO recommended increasing the ritonavir boosting dose to 400 mg every 12 h with lopinavir when concomitantly used in combination with rifampicin \[[@CR21]\] however this has been associated with poor tolerability and hepatotoxicity \[[@CR27]--[@CR29]\]. More recently, raltegravir was reported to be an adequate alternative to efavirenz in TB/HIV co-infected patients in a phase 2 trial \[[@CR30]\]. Therefore, CDC and WHO both indicate raltegravir to be the preferred option when efavirenz is contraindicated, or the use of rifabutin when ritonavir-boosted protease inhibitors are necessary \[[@CR1], [@CR16], [@CR18], [@CR31]\]. However, access to rifabutin and raltegravir in low- and middle-income countries, is often difficult or impossible \[[@CR30]\]. The aim of this study was to assess clinical outcomes (mortality, virological suppression, loss to follow-up during the first year following TB diagnosis) across different regions (Eastern Europe, Western Europe, and Latin America) among HIV-positive adult patients treated with efavirenz and non-efavirenz containing ART regimens.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The TB:HIV study is a collaboration between TB and HIV clinicians from 19 countries in Europe and Latin America. Patients aged 16 years or older were included if they were HIV-positive and were diagnosed with TB between January 1, 2011, and December 31, 2013. Patients with confirmed TB (*Mycobacterium tuberculosis* on culture or PCR), probable TB (Acid-Fast Bacilli on 'smear' or granulomatous inflammation on biopsy specimens) and presumptive TB (empiric TB treatment initiated, and with a TB diagnosis not subsequently ruled out) were included in the study. Details of the TB:HIV study have been published elsewhere \[[@CR2]\]. For the main analysis, those who initiated tuberculosis treatment and ART concomitantly were analyzed. Data on TB and HIV disease, including demographic, clinical, laboratory parameters, and clinical outcomes were collected prospectively on standardized case report forms (<http://www.cphiv.dk>). Due to the observational nature of the study, all decisions regarding use of tuberculosis and ART treatment regimens was at the discretion of individual clinicians.

Statistical analyses {#Sec4}
--------------------

In this study, patients were categorized into two groups according to their ART regimen. In the efavirenz group patients who initiated an efavirenz-containing ART regimen within 3 months of starting TB therapy, or who were receiving it (at least in the 2 weeks before TB diagnosis) were included. Patients, who interrupted ART for more than 15 days while on anti-TB drugs, were excluded. In the non-efavirenz group, patients receiving ART but not containing efavirenz within the above time frame were included. Patients in this group included those in receipt of ritonavir-boosted protease inhibitors, triple nucleoside reverse transcriptase inhibitors, integrase inhibitors or nevirapine. Baseline was considered the date anti-TB treatment was commenced. Demographic and clinical characteristics of patients at baseline were described by receipt of ART in each region and for all study participants. Patients were recorded as dead, in care with virological suppression, in care without virological suppression, in care without viral load information, or lost to follow up at 12 months after their TB diagnosis. A viral load \< 400 copies/mL between 8 and 12 months after baseline was considered as virological suppression. Patients with a last visit date reported before 12 months of follow-up were considered lost to follow up. All patients were included in analysis of time to outcome, and were censored 12 months after the TB diagnosis.

The main outcome was mortality during the first year following TB diagnosis comparing efavirenz and non-efavirenz containing ART regimens, using three different statistical methods to account for potential confounders and bias: inverse probability weighting, Cox models and marginal structural models. For the first method, Kaplan-Meier survival curves were estimated using inverse weighting. Weights were calculated from a logistic model to predict efavirenz use, adjusting by traditional confounders: region, age, gender, CD4 count at TB diagnosis, type of TB, route of HIV transmission, naïve status, rifamycin use (rifampicin or rifabutin), and multidrug-resistant TB (MDR-TB). In the second method, a Cox model was used to estimate risk of death using the same co-variables, stratifying by naïve status. Continuous variables such as age and CD4 cell count were included in the models using splines with three knots to fit a non-linear and less biased relationship with the outcome \[[@CR32]\]. Finally, a marginal structural model was used to estimate the effect of both ART regimes on mortality in the presence of varying time co-variables (time-dependent confounders), as well as type of rifamycin used, CD4 count, and resistance to anti-TB drugs (variables that could affect choice of ART regimen). With this method, simulation of a clinical trial comparing two regimes of ART in HIV individuals co-infected with TB, controlling by time updated measurements of the confounders, was attempted. To achieve this, a monthly data set was generated for each patient selected from the time of TB diagnosis until 12 months of follow-up, recording all the socio-demographic and clinical endpoints month by month.

Following standard use of marginal structural models, patients who did not receive ART at initiation of TB treatment were included in this analysis since, as they were on tuberculosis treatment, they had the potential to be started by clinicians on ART with any regimen, as in local clinical practice \[[@CR33]\]. The dataset was expanded in order to have the same patients and their characteristics in either of two possible regimens of ART (efavirenz-containing, or not), and artificial censoring was created to keep only the time in which patients did not leave the regimen. To adjust for a potential bias due to unbalance of co-variables in each regimen stabilized weights from two logistic models were built to predict use of ART controlling by time, age, gender, region, naive status, rifamycin use, injection drug use (IDU) status, type of TB (disseminated compared to pulmonary), CD4 count, and MDR-TB. The probability of death was estimated with a pooled logistic regression model using the ART regimen, time in months, region, CD4 count, gender, naïve status, MDR-TB status, with rifamycin receipt as a co-variable and with stabilized weights \[[@CR33]\]. Sensitivity analysis was done including only ART-naïve patients. Cox models adjusted by traditional confounders were used, looking for factors related to virological suppression among patients at 12 months after diagnosis of TB who were in care with a viral load available, and who were lost to follow up.

Results {#Sec5}
=======

Of 1389 patients in the study, 965 (69%) received ART during the predefined time-frame and were included in the main analysis: 647 were in the efavirenz group and 318 in the non-efavirenz group. We excluded 177 patients because they started ART after the time-frame (i.e. \> 3 months after initiation of TB treatment), and 18 because of ART interruptions (\> 15 days) during TB treatment. Baseline characteristics of participants stratified by ART regimen and ART status are shown in Table [1](#Tab1){ref-type="table"}. Patients were treated with a rifamycin (rifampin or rifabutin) for a median of 7 months (IQR: 2--10). Patients had a median of one viral load measurement during the first year following ART initiation (IQR: 0--2).Table 1Demographic and clinical characteristics of patients at the time of starting TB therapyAll (*N* = 965)ART naïve (*N* = 518)Non ART naïve (*N* = 447)Efavirenz (*n* = 647)non Efavirenz (*n* = 318)Efavirenz (*n* = 420)non Efavirenz (*n* = 98)Efavirenz (*n* = 227)non Efavirenz (*n* = 220)Patient age at TB diagnosis (years)37 (31--43)37 (31--45)37 (32--44)35 (32--43)36 (31--42)38 (31--47)Male^\*^, n(%)499 (77%)206 (65%)345 (82%)73 (74%)154 (68%)133 (60%)Ethnic group, n(%)^\*+&^ White432 (68%)182 (60%)298 (73%)61 (68%)134 (60%)121 (56%) Hispanic118 (19%)43 (14%)63 (15%)10 (11%)55 (25%)33 (15%) Black47 (7%)62 (20%)26 (6%)14 (16%)21 (9%)48 (22%) Other35 (6%)18 (6%)22 (5%)5 (6%)13 (6%)13 (6%)HIV risk, n(%)^\*^ non IDU382 (59%)211 (66%)243 (58%)56 (57%)139 (61%)155 (70%) IDU265 (41%)107 (34%)177 (42%)42 (43%)88 (39%)65 (30%)Region, n(%)^\*+&^ Eastern Europe363 (56%)118 (37%)262 (62%)50 (51%)101 (44%)68 (31%) Western/Southern Europe131 (20%)144 (45%)77 (18%)39 (40%)54 (24%)105 (48%) Latin America153 (24%)56(18%)81 (19%)9 (9%)72 (32%)47 (21%)CD4^+^ count (cells/mm^3^)^\*+^96 (33--210)118 (34--310)82 (29--164)60 (18--118)140(48--297)168(56--372)Missing CD4 counts, n (%)3 (\< 1%)1 (\< 1%)3 (1%)1 (1%)0(0%)0(0%) HIV RNA (copies/mL),  n(%)^\*^ \< 40076 (12%)63(20%)8 (2%)2 (2%)68 (30%)61 (28%) 400--10 000039 (6%)36 (11%)18 (4%)4 (4%)21 (9%)32 (14%)  \> 10 0000319 (49%)121 (38%)254(60%)61 (62%)65 (29%)60 (27%) Unknown213 (33%)98 (31%)140 (33%)31 (32%)73 (32%)67 (30%)Haemoglobin (g/dL)12 (10--14)12 (10--14)12 (10--14)12 (10--13)13 (10--14)12 (10--14)Disseminated TB^+^, n(%)373 (58%)189 (59%)74 (76%)237 (56%)136 (60%)115 (52%)Resistance test performed348 (54%)169 (53%)226 (54%)49 (50%)122 (54%)120 (54%)MDR-TB, n(%)°68 (19%)20 (12%)47 (21%)12 (24%)21 (17%)8 (7%)Initial anti-TB drug, n(%)^\*+&^ Rifampicin587 (91%)208 (65%)390 (93%)70 (71%)197 (87%)138 (63%) Rifabutin13 (2%)69 (22%)9 (2%)12 (12%)4 (2%)57 (26%) No rifamicin47 (7%)41 (13%)21 (5%)16 (16%)26 (11%)25 (11%)ART regimen, n (%) Efavirenz647 (100%)0 (0%)420 (100%)0 (0%)227 (100%)0 (0%) Protease inhibitor0 (0%)181 (57%)0 (0%)62 (63%)0 (0%)119 (54%) Integrase inhibitor0 (0%)70 (22%)0 (0%)23 (23%)0 (0%)47 (21%) Other0 (0%)67 (21%)0 (0%)13 (13%)0 (0%)54 (25%)Time between TB therapy and ART initiation (days)^&^----28 (17--49)28 (15--34)376 (47--1198)1337 (199--3484)*Note:* Continuous variables are reported as medians and interquartile ranges. ^\*^*p* \< 0.05 between patients receiving efavirenz and non-efavirenz -containing regimens of ART including the entire cohort. ^+^*p* \< 0.05 between efavirenz and non-efavirenz-containing ART regimens, including only naïve patients^&^*p* \< 0.05 between efavirenz and non-efavirenz including only non-naïve patients. Time between TB diagnosis and ART initiation was estimated between non-naïve patients as TB diagnosis date less first ART date. °Percentage estimated relative to those with resistance test performed*IDU* Injecting Drug User*,* MDR-TB Multi-drug resistant tuberculosis

Clinical outcomes at 12 months {#Sec6}
------------------------------

Mortality, the proportion of patients with undetectable viral loads, and loss to follow up was similar for patients receiving efavirenz and non-efavirenz ART regimens, irrespective of whether patients were ART-naïve or ART-experienced at TB diagnosis (Table [2](#Tab2){ref-type="table"}). Clinical outcomes differed significantly across regions, although within regions, similar outcomes were observed for patients receiving efavirenz and non-efavirenz ART regimens (Fig. [1](#Fig1){ref-type="fig"}). The highest proportion of deaths and the lowest proportion of patients with undetectable HIV viral loads at 12 months were observed in EE. Many patients in all regions had no viral load information in the time window 8--12 months following TB diagnosis: 25% in EE, 17% in WE, and 23% in LA) for those receiving an efavirenz-containing regimen (*p* \< 0.01), and 32%, 15% and 25% for those taking a non-efavirenz regimen, respectively (*p* \< 0.01) (Fig. [1](#Fig1){ref-type="fig"}).Table 2Outcomes at 12 months in the entire cohort, naïve and non-naïve patients, by ART regimenAllART naïveART non-naïveEfavirenz (n = 647)non Efavirenz (n = 318)Efavirenz (n = 420)non Efavirenz (n = 98)Efavirenz (n = 227)non Efavirenz (n = 220)Death84 (13%)29 (9%)51 (12%)10 (10%)33 (14%)19 (9%)LTFU129 (20%)50 (16%)100 (24%)20 (20%)29 (13%)30 (14%)Undetectable HIV-RNA220 (34%)132 (41%)134 (32%)35 (36%)86 (38%)97 (44%)Detectable HIV-RNA67 (11%)34 (11%)44 (10%)8 (8%)23 (10%)26 (12%)Active no VL147 (23%)73 (23%)91 (22%)25 (25%)56 (25%)48 (22%)*p* value0.080.780.27Note: *p* values reflect the comparison of the overall distribution of outcomes for efavirenz- and non-efavirenz containing ART regimens*LTFU* lost to follow-up, *HIV-RNA Undetectable* VL \< 400 at 12 months, *VL* viral loadFig. 1Outcomes at 12 months by region and ART regimen. EFV: Efavirenz, LTFU: loss to follow-up. HIV-RNA undetectable: VL \< 400 copies/ml at 12 months

Survival {#Sec7}
--------

By 12 months 113(12%) deaths had occurred: 84(13%) in the efavirenz group and 29(9%) in the non-efavirenz group. Using an inverse probability weighting method, no difference in survival (adjusted by region, age, gender, CD4 count at TB diagnosis, type of TB, route of HIV transmission, naïve status, rifamycin use at TB diagnosis, and MDR-TB) was observed between efavirenz and non-efavirenz treated individuals (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). In adjusted Cox regression models stratified by ART status and use of rifamycin, the hazard ratio (HR) for death was 1.13 (95% CI: 0.72--1.78; *p* = 0.59) for efavirenz compared with non-efavirenz ART regimens (Table [3](#Tab3){ref-type="table"}). In the same model, higher CD4 counts at TB diagnosis were associated with a lower risk of death (HR 0.27, 95%CI: 0.17--0.42, *p* \< 0.001) for patients with CD4 of 350 cells/mm^3^ compared to those with CD4 50 cells/mm^3^, and naïve patients had a lower risk of death (HR 0.64, 95%CI: 0.43--0.96, *p* = 0.03) (Table [3](#Tab3){ref-type="table"}). Gender, age, route of HIV transmission, disseminated TB, and MDR-TB were not significantly associated with mortality. Survival analysis stratified by ART status showed lower mortality among naïve compared with non-naïve patients, but there were no differences between patients receiving either efavirenz or non-efavirenz ART regimens (Additional file [1](#MOESM1){ref-type="media"}: Figure S2).Table 3Risk factors for death. Univariate and multivariate Cox modelsUnivariate modelMultivariate modelHazard Ratio (95% confidence interval)*p*-valueHazard Ratio (95% confidence interval)p-valueRegion\< 0.01\< 0.01 Eastern Europe11 Western/Southern Europe0.16(0.08--0.31)0.19 (0.09--0.39) Latin America0.42(0.25--0.70)0.44 (0.25--0.77)Age, years0.690.87 30 vs 201.07(0.64--1.80)1.12 (0.64--1.97) 40 vs 201.07(0.47--2.42)1.29 (0.53--3.13) 50 vs 200.93(0.43--2.00)1.53 (0.66--3.55)Male1.26(0.81--1.95)0.301.00 (0.62--1.60)0.99Disseminated TB1.57(1.06--2.33)0.031.38 (0.92--2.06)0.12IDU1.89(1.31--2.74)\< 0.011.19 (0.78--1.83)0.42TB susceptibility\< 0.010.52 No MDR vs MDR0.41(0.24--0.71)0.72 (0.41--1.27) No Resistance test vs MDR0.52(0.31--0.88)0.84(0.49--1.46)Efavirenz1.47(0.96--2.24)0.071.13(0.72--1.78)0.59ART naïve1.06(0.73--1.54)0.740.64(0.43--0.96)0.03CD4^+^ at TB diagnosis (cells/mm^3^)\< 0.01\< 0.01 100 vs 500.63(0.53--0.76)0.61(0.50--0.73) 200 vs 500.35(0.25--0.51)0.33(0.23--0.48) 350 vs 500.27(0.17--0.42)0.27(0.17--0.42)Note: Cox regression model in which patients were stratified by rifamicin use at TB diagnosisNine hundred sixty-five patients were included in this model. *IDU* Injection Drug User, *MDR-TB* Multi-drug resistant tuberculosis

Marginal structural models {#Sec8}
--------------------------

Of the 1389 patients in the prospective HIV:TB study 229(16.5%) never started ART and were therefore, only included in the marginal structural model. Of these 229 patients 92% were from EE, 4% from WE and 3% LA. Their median CD4 cell count was 149 cells/uL. 60% were IDU, 38% had MDR-TB and 65% had disseminated TB (see Additional file [1](#MOESM1){ref-type="media"}: Table S2). Overall 117(51%) died, and at 12 months after TB diagnosis 75(33%) were lost to follow up. Using the marginal structural model the odds of death (OR) for those in receipt of an efavirenz-containing ART regimen was 0.82 (95%CI: 0.66--1.02, *p* = 0.08, when compared to those receiving a non-efavirenz containing regimen. After truncating weights for different percentiles, such as 95%, the mortality odds remained non-significant (OR 0.85 (95%CI: 0.67--1.07, *p* = 0.18). These results, obtained using this model were consistent with the other statistical techniques used in this study. Furthermore exploration, in an analysis restricted to patients starting efavirenz compared with those starting a ritonavir-boosted protease inhibitor regimen only, showed that the odds of death for those who started an efavirenz-containing ART regimen was statistically better (OR 0.76, 95%CI: 0.60--0.95, *p* = 0.01).

Sensitivity analysis for mortality among ART-naïve patients {#Sec9}
-----------------------------------------------------------

This analysis included 518 ART-naïve patients: 420 (81%) receiving efavirenz-based ART and 98 (19%) non-efavirenz containing ART. Adjusted survival curves are shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S3 and the Cox model results are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1. In the marginal structural model, odds of death were better in those receiving efavirenz-based ART: OR 0.55 (95%CI: 0.36--0.85, *p* \< 0.01). Truncating at other percentiles showed similar results. Additional file [1](#MOESM1){ref-type="media"}: Figure S4 and Table S3 show the results for ART-non naïve patients.

Virological suppression {#Sec10}
-----------------------

Among 453 of the original 965 patients who still were alive and in care at 12 months, and who had viral load information available, 352 (77%) patients had undetectable plasma HIV viral loads (less than 400 copies/ml). The proportion of patients with virological suppression was less frequent in EE, regardless of the ART regimen, compared to the other regions. Distribution by ART regimen and treatment experience is shown in Table [2](#Tab2){ref-type="table"}. In an adjusted Cox model, the hazard ratio (HR) for virological suppression was 0.97 (95%CI: 0.76--1.22: *p* = 0.77) for efavirenz, compared with non-efavirenz containing ART regimens. Gender, age, route of HIV transmission, disseminated TB, rifamycin use, being ART-naïve, and having documented MDR-TB were not significantly associated with virological suppression (Table [4](#Tab4){ref-type="table"}).Table 4Factors associated with virological successUnivariate modelMultivariate modelHazard Ratio (95% confidence interval)*p*-valueHazard Ratio (95% confidence interval)*p*-valueRegion0.07\< 0.01 Eastern Europe11 Western/Southern Europe0.99(0.77--1.27)1.03 (0.75--1.41) Latin America1.29(0.97--1.73)1.42 (1.04--1.94)Age, years0.590.87 30 vs 201.13(084--1.52)1.12 (0.83--1.51) 40 vs 201.24(0.76--2.02)1.22 (0.74--2.01) 50 vs 201.26(0.80--2.00)1.28 (0.80--2.06)Male1.01(0.81--1.27)0.910.93 (0.73--1.18)0.53Disseminated TB0.90(0.73--1.12)0.340.86 (0.69--1.07)0.17IDU1.07(0.85--1.34)0.581.16 (0.87--1.55)0.30TB susceptibility0.790.84 No MDR vs MDR1.07(0.65--1.75)1.05(0.62--1.78) No Resistance test vs MDR1.04(0.63--1.72)0.98(0.58--1.66)Rifamicin1.25(0.79--1.97)0.33Efavirenz1.05(0.84--1.30)0.680.97(0.76--1.22)0.77ART naïve1.11(0.90--1.37)0.331.09(0.86--1.39)0.44CD4^+^ at TB diagnosis (cells/mm^3^)0.480.41 100 vs 500.99(0.90--1.08)0.99(0.90--1.10) 200 vs 500.96(0.79--1.16)0.98(0.79--1.20) 350 vs 500.91(0.73--1.14)0.92(0.73--1.17)Note: Only 453 patients in care at 12 months were included in this model. Patients without HIV-RNA information were excluded, *n* = 220*IDU* Injection Drug User, *MDR-TB* Multi-drug resistant tuberculosis

Loss to follow-up {#Sec11}
-----------------

Of the 852 patients included in this analysis, which only excluded patients who died, 179 (21%) were lost to follow up at 12 months (Table [2](#Tab2){ref-type="table"}). In a Cox model, adjusted for gender, age, region, CD4 count at diagnosis of TB, loss to follow-up was similar among those receiving an efavirenz-containing regimen of ART, when compared with non-efavirenz containing regimens: HR 1.17 (95% CI: 0.81--1.67: *p* = 0.40). However, a higher risk of loss to follow-up was found in patients from EE, compared to patients from other regions (Table [5](#Tab5){ref-type="table"}).Table 5Risk factors for loss to follow-upUnivariate modelMultivariate modelHazard Ratio (95% confidence interval)p-valueHazard Ratio (95% confidence interval)*p*-valueRegion\< 0.01\< 0.01 Eastern Europe11 Western/Southern Europe0.59(0.41--0.84)0.77(0.50--1.16) Latin America0.58(0.39--0.87)0.64(0.41--1.00)Age, years0.59a 30 vs 201.20(0.79--1.83) 40 vs 201.20(0.63--2.29) 50 vs 200.82(0.85--1.50)Male1.00(0.73--1.40)0.960.90(0.64--1.28)0.56Disseminated TB0.89(0.66--1.19)0.440.93(0.68--1.26)0.62IDU1.25(0.93--1.69)0.130.97(0.68--1.37)0.85TB susceptibility0.520.84 No MDR vs MDR0.72(0.41--1.26)0.92(0.51--1.65) No Resistance test vs MDR1.19(0.69--2.05)1.45(0.83--2.52)Rifamicin0.84(0.50--1.41)0.51aEfavirenz1.38(0.99--1.91)0.061.17(0.81--1.67)0.40ART naïve1.94(1.42--2.65)\< 0.01aCD4^+^ at TB diagnosis (cells/mm^3^)0.480.41 100 vs 500.97(0.86--1.10)0.99(0.90--1.10) 200 vs 500.95(0.73--1.25)0.98(0.79--1.20) 350 vs 500.98(0.72--1.34)0.92(0.73--1.17)Note: Multivariate Cox model regression stratified by ryfamicin use, naïve condition and age. ^a^For these variables the model was stratified so we do not have specific hazard ratios. Eight hundred fifty-two patients included, only people who died at 12 months were excluded in this model

Discussion {#Sec12}
==========

In this prospective observational study, there were major differences in outcomes that were predicated by patients' region of residence. The mortality in Eastern Europe was significantly higher than in other regions, as described previously \[[@CR3], [@CR34], [@CR35]\], but this did not differ significantly according to ART regimen (either efavirenz or non-efavirenz containing ART). Although ART-naïve patients had slightly better survival in comparison to ART non-naïve patients, this was similar for patients receiving efavirenz and non-efavirenz containing ART regimens. Furthermore, the proportions of patients who became lost to follow up and who had undetectable viral loads at 12 months following diagnosis of TB did not differ according to whether efavirenz was included in the ART regimen.

The observed similar survival in patients treated with efavirenz or non-efavirenz regimens may have several explanations, including that the non-efavirenz group was heterogeneous. Although inverse probability weighting was used to balance the differences in the co-variables between groups, it is possible that not all confounders including socio-demographic factors, comorbidities and/or concomitant (opportunistic) infections, diagnostic delay, and access to anti-TB drug susceptibility tests were included. In contrast with previously described findings in this cohort, MDR-TB was not associated with mortality at 12 months, probably because those with MDR-TB were less likely to start antiretroviral therapy and were therefore not included in the current study: moreover, a resistance test was performed in only 54% of the selected population. In the main model used, no differences in mortality between regimes was observed, but in an explorative marginal structural model restricted just to patients treated with a boosted protease inhibitor or efavirenz, survival was statistically different, favoring the group receiving efavirenz-based ART. This finding may reflect poorer tolerability of protease inhibitors, greater frequency of drug-drug interactions, or previous virological failure that could additionally impact on mortality. Surprisingly, there was a high proportion of subjects receiving PI-based ART as their first regimen (57%). This group of patients were mostly in the Eastern European region (61%), and most likely the reason for initiating ART with a PI-containing regimen was because of the local availability. Moreover, only 22% of those on non-efavirenz regimens received integrase inhibitors, a majority from Western Europe. Any inferences based on outcomes with this class of ART should be interpreted with caution as the study was not designed to directly compare integrase inhibitors with efavirenz, and additionally, the main analysis may have lacked power to detect a survival benefit.

The proportion of patients who were lost to follow up was high, especially among patients from Eastern Europe, irrespective of ART regimen. This is consistent with findings from other studies in countries with a high burden of TB \[[@CR36]\]. Higher rates of loss to follow up in some other studies may be explained by differences in patient populations, health care provision models including more assertive outreach to patients who have dropped out of care. Although frequency of patients with virological suppression at 12 month was overall acceptable (77%), the proportion of plasma HIV-RNA determinations was heterogeneous between regions. Nevertheless, if the goal is to reach the 90--90-90 target, this rate of virological suppression is still some way from being accomplished. No clinical factors associated with an undetectable HIV viral load were found in this study, however it was less likely to be achieved in Eastern Europe. In general, unfavorable outcomes such as loss to follow-up, proportion of detectable viral load and mortality were more frequent in the Eastern European region, which is consistent with previous publications from our study \[[@CR2], [@CR3]\]. Factors such as characteristics of the HIV population (i.e. the high proportion of IDU), education and health care barriers, less access to HIV monitoring such as HIV-RNA determinations, and the feasibility of implementing current recommendations on ART initiation in the context of an AIDS-defining event \[[@CR37]\], might have an important role when patients are compared with other regions with limited healthcare resources, such as Latin America.

Our study has several limitations. These include the relatively short follow-up period, differences between regions in terms of routine care such as access to HIV-RNA determinations, heterogeneity of use of ART, availability of rifabutin and integrase inhibitors, and timing of ART initiation at TB diagnosis. In terms of data availability, we recognize limitations in information regarding reasons for initiating or changing specific ART regimens, which did not allow us to accurately distinguish between changes due to adverse effects or changes due to ART failure and we cannot exclude the possibility that some naïve patients might have been receiving ART -- although this was not detected during our quality assurance procedures. However, this is the largest multi-regional TB:HIV cohort and the first to comprehensively compare the concomitant use of TB treatment and efavirenz and non-efavirenz containing ART regimes. Using marginal structural models, there was a slightly better outcome for patients treated with efavirenz-containing ART, although this was not consistent in all analyses and therefore not categorical. These results warrant further analyses.

Conclusions {#Sec13}
===========

In this multi-centre, multi-region cohort study, overall, poor outcomes were more frequent in Eastern Europe. Use of efavirenz or non-efavirenz containing ART regimens did not impact on mortality, virological suppression, or loss to follow-up at 12 months following diagnosis of TB. Considering these differences between regions irrespective of ART regimen, more, prospective studies are needed, particularly in resource-constrained regions in which access to rifabutin and integrase inhibitors is still limited.
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TB:HIV Study group.

*Eastern Europe*: Belarus: Belarusian State Medical University, Department of Infectious Disease: I. Karpov (PI), A. Vassilenko; Republican Research and Practical Centre for Pulmonology and TB (Minsk): A. Skrahina (PI), D. Klimuk, A. Skrahin, O. Kondratenko and A. Zalutskaya; Gomel State Medical University (Gomel): V. Bondarenko (PI), V. Mitsura, E. Kozorez, O. Tumash; Gomel Region Centre for Hygiene: O. Suetnov (PI) and D. Paduto. Estonia: East Viru Central Hospital (Kohtla-Jarve): V. Iljina (PI) and T. Kummik. Georgia: Infectious Diseases, AIDS and Clinical Immunology Research Center (Tiblisi): N. Bolokadze (PI), K. Mshvidobadze and N. Lanchava; National Center for Tuberculosis and Lung Diseases of Georgia (Tibilisi): L. Goginashvili, L. Mikiashvili and N. Bablishvili. Latvia: Infectology Centre of Latvia (Riga): B. Rozentale (PI), I. Zeltina and I. Janushkevich. Lithuania: Centre for Communicable Diseases and AIDS (Vilnius): I. Caplinskiene (PI), S. Caplinskas, Z. Kancauskiene. Poland: Wojewodski Szpital Zakanzy/Medical University of.

Warsaw (Warszawa): R. Podlasin (PI), A. Wiercinska-Drapalo (PI), M. Thompson and J. Kozlowska; Wojewodski Szpital Specjalistyczny/Medical University Teaching Hospital (Bialystok): A. Grezesczuk (PI); Jozef Strus Multidisciplinary City Hospital (Poznan): M. Bura (PI); Wroclaw University School of Medicine (Wroclaw): B. Knysz (PI) and M. Inglot; Jagiellonian University Medical College (Krakow): A. Garlicki (PI) and J. Loster. Romania: Dr. Victor Babes Hospital (Bucharest): D. Duiculescu († PI) and S. Tetradov. Russia: Botkin Hospital of Infectious Diseases (St. Petersburg): A. Rakhmanova († PI), O. Panteleeva, A. Yakovlev, A. Kozlov, A. Tyukalova and Y. Vlasova; City TB Hospital No. 2 (St. Petersburg): A. Panteleev (PI); Center for Prevention and Control of AIDS (Veliky, Novgorod): T. Trofimov (PI); Medical University Povoljskiy Federal Region. Ukraine: Crimean Republican AIDS Centre (Simferopol): G. Kyselyova (PI).

*Western Europe*: Belgium: CHU Saint-Pierre (Brussels): M.C. Payen (PI), K. Kabeya and C. Necsoi. Denmark: Rigshospitalet (Copenhagen): N. Obel (PI); Hvidovre University Hospital: K. Thorsteinsson. France: Aquitaine Cohort. Cohort administration: F. Dabis (PI) and E. Pernot. Participating Centers and Physicians: Bordeaux University Hospital: P. Morlat; Arcachon Hospital: A. Dupont; Dax Hospital: Y. Gerard; Bayonne Hospital: F. Bonnal; Libourne Hospital: J. Ceccaldi; Mont-de-Marsan Hospital: S. De Witte; Pau Hospital: E. Monlun; Périgueux Hospital: P. Lataste; Villeneuve-sur-Lot Hospital: I. Chossat. Switzerland: Swiss HIV Cohort Study (SHCS, [www.shcs.ch](http://www.shcs.ch)): Cohort administration: M. Sagette and M. Rickenbach. Participating Centers and Physicians: University Hospital Basel: L. Elzi and M. Battegay; University Hospital Bern: H. Furrer (PI); Hopital Cantonal Universitaire, Geneve: D. Sculier and A. Calmy; Centre Hospitalaire Universitaire Vaudois, Lausanne: M. Cavassini; Hospital of Lugano: A. Bruno and E. Bernasconi; Cantonal Hospital St. Gallen: M. Hoffmann and P. Vernazza; University Hospital Zurich: J. Fehr and R. Weber. This study has been co-financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant \#148522) and by SHCS project 666. The data are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and 36 private physicians). The members of the Swiss HIV Cohort Study are: V. Aubert, M. Battegay, E. Bernasconi, J. Böni, H.C. Bucher, C. Burton-Jeangros, A. Calmy, M. Cavassini, G. Dollenmaier, M. Egger, L. Elzi, F. Fehr, J. Fellay, H. Furrer (Chairman of the Clinical and Laboratory Committee), C.A. Fux, M. Gorgievski, H. Günthard (President of the SHCS), D. Haerry (deputy of "Positive Council"), B. Hasse, H.H. Hirsch, M. Hoffmann, I. Hösli, C. Kahlert, L. Kaiser, O. Keiser, T. Limkait, R. Kouyos, H. Kovari, B. Ledergerber, G. Martinetti, B. Martinez de Tejada, K. Metzner, N. Müller, D. Nadal, D. Nicca, G. Pantaleo, A. Rauch (Chairman of the Scientific Board), S. Regenass, M. Rickenbach (Head of Data Center), C. Rudin (Chairman of the Mother & Child Sub-study), F. Schöni-Affolter, P. Schmid, J. Schüpbach, R. Speck, P. Tarr, A. Telenti, A. Trkola, P. Vernazza, R. Weber, S. Yerly. United Kingdom: Mortimer Market Centre (London): R.F. Miller (PI) and N. Vora; St. Mary's Hospital (London): G. Cooke (PI) and S. Mullaney; North Manchester General Hospital: E. Wilkins (PI) and V. George; Sheffield Teaching Hospitals: P. Collini (PI) and D. Dockrell; King's College Hospital (London): F.A. Post (PI), L. Campbell, R. Brum, E. Mabonga and P. Saigal. Queen Elizabeth Hospital: S. Kegg (PI); North Middlesex University Hospital: J. Ainsworth (PI) and A. Waters. Leicester Royal Infirmary: J. Dhar (PI) and L. Mashonganyika. Southern Europe: Italy: IRCCS - Ospedale L. Spallanzani (Rome): E. Girardi (PI), A Rianda, V. Galati, C. Pinnetti and C. Tommasi; AO San Gerardo (Monza): G. Lapadula (PI); IRCCS AOU San Martino -- IST di Genoa (Genova): A. Di Biagio (PI) and A. Parisini; Clinic of Infectious Diseases, University of Bari (Bari): S. Carbonara (PI), G. Angarano and M. Purgatorio; University of Brescia Spedali Civili: A. Matteelli (PI) and A. Apostoli. Spain: Barcelona Cohort funded by the Spanish HIV/AIDS Research Network: Hospital Clinic of Barcelona: J.M. Miro (PI), C. Manzardo, C. Ligero and J. Gonzalez; Hospital del Mar: F. Sanchez, H. Knobel, M. Salvadó and J.L. Lopez-Colomes; Mutua de Terrassa: X. Martínez-Lacasa and E. Cuchí; Hospital Universitari Vall d'Hebrón: V. Falcó, A. Curran, M.T. Tortola, I. Ocaña and R. Vidal; Hospital Universitari de la Santa Creu i Sant Pau: M.A. Sambeat, V. Pomar and P. Coll; Hospital Universitari de Bellvitge: D. Pozamczer, M. Saumoy and F. Alcaide; Agencia de Salud Pública de Barcelona: J. Caylà, A. Moreno, J.P. Millet, A. Orcau, L. Fina, L. del Baño, L.L. Roldan. Hospital Universitario Donostia (San Sebastian): JA. Iribarren (PI) and M. Ibarguren; Hospital Universitario Ramon y Cajal (Madrid): S. Moreno (PI) and A. González; Hospital Universitario 'Gregorio Maranon' (Madrid): P. Miralles (PI) and T. Aldámiz-Echevarría.

*Latin America*: Argentina: The CICAL Cohort: Cohorte administration: M. Losso (PI), J. Toibaro and L. Gambardella. Participating Centers and Physicians: Argentina: Hospital J. M. Ramos Mejía (Buenos Aires): J. Toibaro and L. Moreno Macias; Hospital Paroissien (BA): E. W arley (PI) and S. Tavella; Hospital Piñero (BA): O. Garcia Messina and O. Gear; Hospital Nacional Profesor Alejandro Posadas: H. Laplume; Hospital Rawson (Cordoba): C. Marson (PI); Hospital San Juan de Dios (La Plata): J. Contarelia and M. Michaan; Hospital General de Agudos Donación F. Santojani: P. Scapellato and D. D Alessandro; Hospital Francisco Javier Muñiz (BA): B. Bartoletti and D. Palmero; Hospital Jujuy: C. Elias. Chile: Fundación Arriaran (Santiago): C. Cortes. México: INNCMSZ (México DF): B. Crabtree (PI); Hospital Civil de Guadalajara (Guadalajara): J. Andrade (PI); Hospital General Regional de Leon-CAPASITS: J.L. Mosqueda Gomez.

† Deceased.

*TB:HIV Steering Committee:* H. Furrer, E. Girardi, M. Bruyand, J.A. Caylá, M. Losso, J.D. Lundgren, A. Panteleev (co-chair), R.F. Miller, J.M. Miro, Å.B. Andersen, S. Tetradov, F.A. Post (co-chair), A. Skrahin and J. Toibaro.

*Statistical centre*: A. Schultze, L. Shepherd, A. Mocroft.

*Coordinating centre:* A.M.W. Efsen, M. Mansfeld, B. Aagaard, B.R. Nielsen, A H. Fisher, R.S. Brandt, D. Raben, D.N. Podlekareva, O. Kirk.
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